A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

NCT00866762 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Polycythemia Vera
Essential Thrombocythemia

Interventions

DRUG: HDAC inhibitor (MK-0683)

Sponsor

Copenhagen University Hospital at Herlev